Zurück
Weiter
|
ängstlich zu sein! Halt ein typisch deutsches Verhalten und in ein paar Tagen wird gejammert und geschimpft was das Zeug hält! Aber jedem das seine!
| |||
| Zeit | Kurs | Stück | |
| 13:20:41 | 0,021 | 50.000 | |
| 12:28:18 | 0,023 | 8.412 | |
| 10:31:51 | 0,023 | 20.000 | |
| 10:30:44 | 0,023 | 12.500 | |
| 10:30:26 | 0,023 | 0 | |
| 10:16:40 | 0,023 | 0 | |
Was ist mit blos mit Dir aufeinmal los?img.wallstreet-online.de/smilies/frown.gif" style="max-width:560px" border=0>
Also ich werde jetzt nicht zum aussteigen trommeln!img.wallstreet-online.de/smilies/cry.gif" style="max-width:560px" border=0>
Die ganze Firma wird bald komplett neu bewertet. Man muß sich nur mal die weltweiten Absatzmöglichkeiten vor Augen führen und Paradigm hat schon mal weltweit agiert und die Vertriebsschienen sind immer noch vorhanden. Das P60 ist die Zukunft pur und wird entsprechend auch den Umsatz erheblich steigern!
Mein Kursziel liegt bei einer Marktkapitalisierung von 10 Mio Dollar und ob es heute ca. 53 Mio Aktien oder morgen ein paar mehr gibt läßt sich jederzeit per Mathematik den Kurswert pro Aktie ausrechnen. Das erste Kurszeil sind die 0,05 Dollar und wenn der Newsflow stimmt dann dürften die 0,10 Dollar in 6 Monaten auch zu ereichen sein.
Wir wissen ja wo der Kurs von Paradigm herkommtcharts.edgar-online.com/ext/...ll?2-6-9-0-0-548-03NA000000PMED alt="** Paradigm M. erhält FDA-Verkaufserlaubnis ** 2400898" title="" rel="nofollow" src="charts.edgar-online.com/ext/...l?2-6-9-0-0-548-03NA000000PMED" style="max-width:560px" border=0>
aber wir sehen auch den return!charting.nasdaq.com/ext/...14-0-0-512-03NA000000PMED-&SF:4|5-WD=484-HT=395- alt="** Paradigm M. erhält FDA-Verkaufserlaubnis ** 2400898" title="" rel="nofollow" src="charting.nasdaq.com/ext/...14-0-0-512-03NA000000PMED-&SF:4|5-WD=484-HT=395-" style="max-width:560px" border=0>
Man kann hier ein wenig Geld verlieren, aber man kann hier aber auch mächtig was verdienen!img.wallstreet-online.de/smilies/rolleyes.gif" style="max-width:560px" border=0>
1-Mar-2006
Other Events, Financial Statements and Exhibits
ITEM 8.01 Other Events
On February 28, 2006, Paradigm Medical Industries, Inc. (the "Company") completed financing involving the sale of $1,500,000 in secured convertible notes. The notes are to be purchased in three traunches of $500,000 each. The Company received the first traunche upon the signing of the definitive investment agreements on February 28, 2006. The Company will receive the second traunche upon the filing of a registration statement with the Securities and Exchange Commission and the third traunche upon the effectiveness of the registration statement. The financing was obtained through The NIR Group of Rosalyn, New York and Laidlaw & Co. (UK) Ltd. of New York City.
Under the terms of the notes, the unpaid principal balance of notes, together with any accrued interest thereon, are due and payable three years after the date of issuance. The unpaid principal balance on the notes that were purchased on February 28, 2006 is due on February 28, 2009. Interest is payable on the notes at 8% per annum, payable quarterly in cash, with six months of interest payable up front. However, the interest rate resets to zero percent for any month in which the stock price is greater than 125% of the initial market price, or $.0275, for each trading date during that month.
The notes are secured by the Company's assets, including the Company's inventory, accounts receivable and intellectual property. The notes are also convertible. The Purchasers have the right to convert their notes at any time into shares of the Company's common stock. The conversion price of the notes is equal to the lesser of (i) $.02 and (ii) the average of the lowest intra-day trading prices during the 20 trading days immediately prior to the conversion date discounted by 40%. However, in no event are the Purchasers allowed to convert any portion of their notes in excess of that portion of the notes upon conversion of which the sum of the number of shares beneficially owned by the Purchasers and the number of shares issuable upon conversion of the portion of the notes with respect to which such determination is being made, would result in beneficial ownership by the Purchasers of more than 4.99% of the Company's outstanding common shares.
The Company has a call option under the terms of the notes. The call option provides the Company with the right to prepay all of the outstanding notes at any time, provided there is no event of default by the Company and the Company's stock is trading at or below $.10 per share. An event of default includes the failure by the Company to pay the principal or interest on the notes when due or to timely file a registration statement as required by the Company or obtain effectiveness with the Securities and Exchange Commission of the registration statement. Prepayment of the notes is to be made in cash equal to either (i) 125% of the outstanding principal and accrued interest for prepayments occurring within 30 days following the issue date of the notes; (ii) 130% of the outstanding principal and accrued interest for prepayments occurring between 31 and 60 days following the issue date of the notes; and (iii) 145% of the outstanding principal and accrued interest for prepayments occurring after the 60th day following the issue date of the notes.
The Company's right to repay the notes is exercisable on not less than ten trading days prior written notice to the Purchasers. For notice purposes, a trading day is any day on which the Company's common stock is traded for any period on the OTC Bulletin Board. Notwithstanding the notice of prepayment, the Purchasers have the right at all times to convert all or any portion of the notes prior to payment of the prepayment amount.
The Company also has a partial call option under the terms of the notes in any month in which the current price of its common stock is below the initial market price of $.02. Under the terms of the partial call option, the Company has the right to pay the outstanding principal amount of the notes plus one-month's interest for that month, which will stay any conversions of the notes by the Purchasers for that month. The principal amount of the notes to be repaid is determined by dividing the then outstanding principal amount of the notes by the maturity of the notes in months, or 36.
As further consideration to the Purchasers of the notes, the Company is required to issue warrants to the Purchaser to acquire an aggregate of 12,000,000 shares of the Company's common stock at an exercise price of $.10 per share. The warrants will have a five year term from the date of issuance, with cashless exercise permitted in the event there is not an effective registration statement registering the warrants. The Company is required to have authorized, and reserved for the purpose of issuance, a sufficient number of shares of its common stock to provide for the full conversion or exercise of the outstanding notes and warrants and the issuance of its common shares in connection therewith (based on the conversion price of the notes and exercise price of the warrants in effect from time to time) and as otherwise required by the notes.
The Company is required to register the shares of its common stock issuable upon the conversion of the notes and the exercise of the warrants. The registration statement must be filed with the SEC within 60 days of the February 28, 2006 closing date and the effectiveness of the registration is to be within 135 days of such closing date. Penalties of 2% of the outstanding principal balance of the notes plus accrued interest are to be applied for each month the registration is not effective within the required time. The penalty may be paid in cash or stock at the option of the Company.
The Company intends to use the proceeds from the financing for purchase of inventory, sales and marketing, and working capital.
(c) Exhibits 10.1 Securities Purchase Agreement with AJW Partners, LLC, AJW Offshore, Ltd., AJW Qualified Partners, LLC and New Millennium Capital Partners II, LLP (the "Purchasers") 10.2 Form of Callable Secured Convertible Note with each of the Purchasers 10.3 Form of Stock Purchase Warrant with each of the Purchasers 10.4 Security Agreement with the Purchasers 10.5 Intellectual Property Security Agreement with the Purchasers 10.6 Registration Statement with the Purchasers |
liest!
Auf jeden Fall kommt es zu einer Kapitalerhöhung und die neuen Aktien werden zum Teil weit über den jetzigen Marktpreis liegen! Es könnte sogar passieren das mit 0,10 Dollar neue Aktien gekauft werden!
Diese wichtige Nachricht kam kurz vor dem Börsenschluß in Amerika heraus. Der Börsenkurs hat daraufhin sofort angezogen.
Ich will hier nicht pushen, aber es könnte durchaus passieren das es in kürze zu einer Kursexplosion kommen könnte! Bei W : O werde ich heute Abend in meinen eigenen Thread weiters darauf eingehen wo ich schon Kurse von 0,10 Dollar in den nächsten 6 Monaten vorausgesagt habe. Ich bin der Meinung das hier was größeres entstehen kann und habe selber gut in diese Aktien eingekauft.
Ich will mich nicht ständig wiederholen, aber an der Berichtsfront zu Paradigm nimmt die Zahl der Repote (Analysen) weiter zu!
| |||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
Press Release Source: Paradigm Medical Industries, Inc.
Paradigm Medical Completes $1.5-Million Financing
Wednesday March 1, 3:31 pm ET
SALT LAKE CITY--(BUSINESS WIRE)--March 1, 2006--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB) today announced it has completed the sale of $1.5 million in secured convertible notes, through Laidlaw & Co. (UK) of New York City, and an institutional investor. The notes are to purchased by the investors in three traunches of $500,000 each. Paradigm Medical received the first traunche upon signing definitive investment agreements on February 28, 2006. The Company will receive the second traunche upon the filing of a registration statement with the Securities and Exchange Commission and the third traunche upon the effectiveness of the registration.
ADVERTISEMENT
"Additional capital is needed at this point to provide the Company will adequate funds to expand global sales and marketing programs, especially for the P60 Ultrasound BioMicroscope," said Paradigm Medical's Chief Executive Officer, Raymond P.L. Cannefax. "Moreover, we will now have adequate funds to purchase additional inventory to satisfy expected strong customer demand for all of our products."
The notes are due three years after issuance and are secured by Paradigm Medical's assets, including inventory, accounts payable and intellectual property. The notes are convertible into shares of the Company's common stock at anytime during their term. The conversion price is equal to the lesser of (a) $0.02 per share or (b) the average of the lowest intra-day trading prices during the 20 trading days immediately prior to the conversion date discounted by 40%.
Interest on the notes is payable at 8% per year, payable quarterly in cash, with six-months of interest payable up front. The notes are callable, with prepayment allowed at any time that the price of Paradigm Medical's stock is $0.10 per share or less.
In addition, Paradigm Medical is required to issue warrants to the investors to acquire an aggregate of 12 million shares of the Company's common stock, at an exercise price of $0.10 per share. The warrants will have a five-year term from the date of issuance, with cashless exercise permitted in the event there is not an effective registration statement registering the warrants.
Paradigm Medical is required to register the shares of its common stock issuable upon the conversion of the notes and the exercise of the warrants. The registration statement must be filed with the SEC within 60 days of the February 28, 2006 closing date and the effectiveness of the registration is to be within 135 days of such closing date.
Paradigm Medical Industries, Inc., currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company's corporate offices are located at 2355 South 1070 West, Salt Lake City, Utah 84119. Call (801) 977-8970 or visit us at www.paradigm-medical.com.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Contact:
Paradigm Medical Industries, Inc.
Raymond P.L. Cannefax, CEO, 801-977-8970
--------------------------------------------------
Source: Paradigm Medical Industries, Inc.
| |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||
Dann kann es nicht mehr weit sein bis zum Startschuß!
|
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 44 | Paradigm steht vor dem Quantensprung! | Knappschaftskass. | lsly | 18.11.08 18:31 | |
| 6 | 333 | Paradigm Medical Industries, Inc. | franzl1 | korted | 27.12.07 14:06 | |
| 5 | 104 | ** Paradigm M. erhält FDA-Verkaufserlaubnis ** | Calibra21 | carpediem7 | 10.07.06 15:40 |
